Le statut de médicament orphelin est un signal positif pour les investisseurs lors de l'introduction en bourse des sociétés de biotechnologie

Philippe Gorry

Post-Print from HAL

Date: 2020
References: Add references at CitEc
Citations:

Published in RARE Rencontres des maladies rares, 2020, Paris, France

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:hal-03148722

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().